Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPICAL: Afatinib + CIMAvax-EGF in EGFR+ NSCLC
NCT03623750Phase 2Completed
- Sponsor
- Instituto Oncológico Dr. Rosell
- Start
- Jul 2018
- Primary completion
- Mar 2020
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cimavax egf in non-small cell lung cancer (NSCLC), sponsored by Instituto Oncológico Dr. Rosell. Primary endpoint: Frequency and severity of Adverse Events at 36 months. Started Jul 2018; status: completed.
02
Drugs
cimavax egf
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03623750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03623750.